

Effective Date: August 19, 2024

TEST CHANGE

HPV Primary Screen by PCR With Reflex to Cytology 3016636, HPV PRMRY

Specimen Requirements:	
Patient Preparation:	
Collect:	Cervical or endocervical specimen with SurePath collection kit. Cervical or endocervical specimen with brush or spatula from ThinPrep collection kit (ARUP supply #41785 ThinPrep (Vial and Broom) or #51369 ThinPrep (Vial, Brush and Spatula)) available online through eSupply using ARUP Connect(TM) or contact ARUP Client Services at 800-522-2787.
Specimen Preparation:	Place collection device in corresponding SurePath or ThinPrep media vial.
Transport Temperature:	Refrigerated
Unacceptable Conditions:	Bloody or dark brown specimens. Specimens in any media other than indicated above.
Remarks:	
Stability:	SurePath - Ambient: 1 month; Refrigerated: 6 months; Frozen: Unacceptable ThinPrep - Ambient: 6 months; Refrigerated: 6 months; Frozen: Unacceptable
Methodology:	Qualitative Polymerase Chain Reaction (PCR)
Performed:	Tue-Sat
Reported:	1-5 days
Note:	For cervical sources, a negative high-risk HPV result does not exclude the possibility of future cytologic abnormalities, underlying CIN2-3, or cancer.
CPT Codes:	87624; if reflexed add 88142; if reviewed by pathologist add 88141
New York DOH Approval Status:	Specimens from New York clients will be sent out to a New York DOH approved laboratory, if possible.
Interpretive Data:	
This test amplifies DNA of HPV16, HPV18 and 12 other high-risk HPV types (31, 33, 35, 39, 45, 51,	

52, 56, 58, 59, 66, and 68) associated with cervical cancer and its precursor lesions. Sensitivity may be affected by specimen collection methods, stage of infection, and the presence of interfering



substances. Results should be interpreted in conjunction with other available laboratory and clinical data. A negative high-risk HPV result does not exclude the presence of other high-risk HPV types, the possibility of future cytologic abnormalities, underlying CIN2-3, or cancer.

Effective Date: August 19, 2024

HPV testing should not be used for screening or management of atypical squamous cells of undetermined significance (ASCUS) in women under age 21.

Reference Interval:

Negative

HOTLINE NOTE: There is a reflexive pattern change associated with this test. One or more orderable or component has been added or removed to the reflexive pattern. Refer to the Hotline Test Mix for interface build information.